康泰生物：子公司荣获江苏省科技进步奖二等奖

Core Viewpoint - Kangtai Biological (300601.SZ) has achieved significant recognition in the field of technological innovation by winning the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2] Group 1 - The project addresses key challenges in the prevention and control of emerging viral infectious diseases, focusing on "rapid confirmation" and "precise prevention" through a series of technological breakthroughs [2] - The core component of the project is the inactivated vaccine platform for enteroviruses, which was independently developed by Minhai Biotechnology, a wholly-owned subsidiary of Kangtai Biological [2] - The innovative, practical, and scientific value of this technology has been highly recognized by expert reviewers [2] Group 2 - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent enterovirus inactivated vaccines (Vero cells), with the quadrivalent vaccine currently in Phase I clinical trials [2] - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2] - Successful development of these vaccines will enhance the company's multi-valent vaccine portfolio, strengthen its core competitiveness, and solidify its market position for sustainable development [2]